UbiquiTx Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
9
UbiquiTx General Information
Description
Developer of a computational platform designed for protein-modulating therapies. The company's platform leverages machine learning and protein engineering to identify peptide sequences, offering features like AI-powered target protein modulation and programmable protein degradation, enabling pharmaceutical industry to address previously difficult-to-target proteins and potentially create new treatments for a wide range of diseases.
Contact Information
Website
www.ubiquitx.comCorporate Office
- 325 Vassar Street
- Cambridge, MA 02139
- United States
Corporate Office
- 325 Vassar Street
- Cambridge, MA 02139
- United States
UbiquiTx Timeline
UbiquiTx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Accelerator/Incubator | 21-Nov-2024 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | 30-Oct-2024 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 01-Sep-2024 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jan-2024 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 01-Jul-2023 | Completed | Generating Revenue | |||
| 3. Seed Round | 05-Apr-2023 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 14-Oct-2022 | Completed | Startup | |||
| 1. University Spin-Out | 01-Jan-2020 | Completed | Startup |
UbiquiTx Patents
UbiquiTx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240335554-A1 | Post-translational modification chimeric molecule | Pending | 04-Apr-2023 | ||
| EP-4616405-A2 | Sequence-based framework to design peptide-guided degraders | Pending | 07-Nov-2022 | ||
| EP-4616405-A4 | Sequence-based framework to design peptide-guided degraders | Pending | 07-Nov-2022 | ||
| US-20260188424-A1 | Sequence-based framework to design peptide-guided degraders | Pending | 07-Nov-2022 | ||
| WO-2024102733-A2 | Sequence-based framework to design peptide-guided degraders | Inactive | 07-Nov-2022 | G16B15/30 |
UbiquiTx Signals
UbiquiTx Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Mass Innovation Network | Accelerator/Incubator | |||
| Merck Digital Sciences Studio | Accelerator/Incubator | Minority | ||
| The Engine | Accelerator/Incubator | |||
| US National Science Foundation | Accelerator/Incubator | |||
| National Institutes of Health | Government | Minority |
UbiquiTx FAQs
-
When was UbiquiTx founded?
UbiquiTx was founded in 2020.
-
Where is UbiquiTx headquartered?
UbiquiTx is headquartered in Cambridge, MA.
-
What is the size of UbiquiTx?
UbiquiTx has 4 total employees.
-
What industry is UbiquiTx in?
UbiquiTx’s primary industry is Biotechnology.
-
Is UbiquiTx a private or public company?
UbiquiTx is a Private company.
-
What is UbiquiTx’s current revenue?
The current revenue for UbiquiTx is .
-
How much funding has UbiquiTx raised over time?
UbiquiTx has raised $400K.
-
Who are UbiquiTx’s investors?
Mass Innovation Network, Merck Digital Sciences Studio, The Engine, US National Science Foundation, and National Institutes of Health are 5 of 9 investors who have invested in UbiquiTx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process